Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist&unknown;, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions

By Jackson L.A.   Holmes S.J.   Mendelman P.M.   Huggins L.   Cho I.   Rhorer J.  

Vaccine, Vol. 17, Iss. 15, 1999-04 ,pp. : 1905-1909

Elsevier

Access to resources Recommend Favorite

Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon- production and local IgA response

By Tomoda T.   Morita H.   Kurashige T.   Maassab H.F.  

Vaccine, Vol. 13, Iss. 2, 1995-02 ,pp. : 185-190

Elsevier

Access to resources Recommend Favorite

Enhancement of immune response to intranasal influenza HA vaccine by microparticle resin

By Higaki M.   Takase T.   Igarashi R.   Suzuki Y.   Aizawa C.   Mizushima Y.  

Vaccine, Vol. 16, Iss. 7, 1998-04 ,pp. : 741-745

Elsevier

Access to resources Recommend Favorite

Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine

By Nichol K.L.   Mallon K.P.   Mendelman P.M.  

Vaccine, Vol. 21, Iss. 17, 2003-05 ,pp. : 2216-2226

Elsevier

Access to resources Recommend Favorite

Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

By Greenbaum E.   Furst A.   Kiderman A.   Stewart B.   Levy R.   Schlesinger M.   Morag A.   Zakay-Rones Z.  

Vaccine, Vol. 20, Iss. 7, 2002-01 ,pp. : 1232-1239

Elsevier

Access to resources Recommend Favorite